Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Participate in our new Ebola study

We are now recruiting volunteers for Oxford Vaccine Group's new Ebola study: Evaluating Optimal Vaccine Schedules against Ebola (EVOLVE)

RECRUITING NOW!

You are invited to take part in a study investigating new vaccines against Ebola virus disease (EVD). The current outbreak of EVD in West Africa is estimated by the World Health Organization to have caused more than 10,000 deaths to date and is still ongoing. There is no specific treatment or cure for Ebola and an effective vaccine would be an important step in controlling the spread of disease. The study is being run by the Oxford Vaccine Group, part of the University of Oxford. 

►       If you are aged 18 to 65 years old and in good health you may be eligible to take part in the study

►       We will provide reimbursement for your time, inconvenience and travel

Interested individuals may attend a screening visit at our site to discuss this further and for their suitability for the study to be assessed.  If you would like to find out more, you can contact us via:

Ebolavaccine.org.uk

01865 857420

info@ovg.ox.ac.uk


This study is being run by the Oxford Vaccine Group, part of the University of Oxford and is funded by Crucell Holland BV.

Similar stories

Oxford-led newborn screening pilot expanded to include all babies in England

Every newborn baby in England will be screened for spinal muscular atrophy (SMA), following the expansion of a pioneering University of Oxford-led pilot that introduced the country’s first routine test for the condition.

A New Era for Childhood Cancer Research: Professor Isidro Cortés Ciriano Appointed as Oxford's First Little Princess Trust Professor of Paediatric Oncology

The Department of Paediatrics at the University of Oxford has appointed Professor Isidro Cortés-Ciriano as its first Little Princess Trust Professor of Paediatric Oncology, marking a major milestone in a partnership dedicated to accelerating the development of new treatments for children with cancer.

Oxford University and King’s College London Join IMPACT Network Study to Advance Understanding of Profound Autism

The University of Oxford and King’s College London (King’s) have joined the Innovative Medicine and Precision Approaches to Clinical Trials (IMPACT) Network, an international collaboration of sites working together to accelerate clinical trial readiness and therapeutic development for autism through a large-scale natural history and clinical endpoint study.

Scientists in the Department of Paediatrics discover antibody combinations that block over 90% of malaria parasite growth

In an important discovery for the next-generation of malaria vaccines, University of Oxford researchers in the Department of Paediatrics, in collaboration with the Scripps Institute, have identified how antibodies can be over 90% effective at preventing malaria parasites from growing in certain combinations.

Oxford Bundibugyo ebolavirus vaccine candidate receives CEPI backing

The Coalition for Epidemic Preparedness Innovations (CEPI) has announced today that it will urgently accelerate the development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda, including one being developed by the Oxford Vaccine Group at the University of Oxford.

Statement on vaccine efforts relating to the Bundibugyo Ebolavirus outbreak in the DRC

In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) is working urgently with Oxford’s own Clinical BioManufacturing Facility and the Serum Institute of India Pvt. Ltd. (SIIPL), to rapidly produce and scale doses of our ChAdOx-based monovalent Bundibugyo Ebolavirus candidate vaccine, ChAdOx1 BDBV.